एलोसेट्रॉन के इंटरैक्शन

Concomitant administration of alosetron and moderate CYP1A2 inhibitors, including quinolone antibiotics and cimetidine, has not been evaluated, but should be avoided unless clinically necessary because of similar potential drug interactions. (एलोसेट्रॉन लेबल, दवाओं के इंटरैक्शन)

Fluvoxamine, a known strong inhibitor of CYP1A2, has been shown to increase mean alosetron plasma concentrations (AUC) approximately 6-fold and prolong the half-life by approximately 3-fold [see Drug Interactions ( 7.1 )] . (एलोसेट्रॉन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Fluvoxamine, a known strong inhibitor of CYP1A2, has been shown to increase mean alosetron plasma concentrations (AUC) approximately 6-fold and prolong the half-life by approximately 3-fold [see Drug Interactions ( 7.1 )] . (एलोसेट्रॉन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Fluvoxamine, a known strong inhibitor of CYP1A2, has been shown to increase mean alosetron plasma concentrations (AUC) approximately 6-fold and prolong the half-life by approximately 3-fold [see Drug Interactions ( 7.1 )] . (एलोसेट्रॉन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Concomitant use of fluvoxamine ( 4.3 ) (एलोसेट्रॉन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Fluvoxamine, a known strong inhibitor of CYP1A2, has been shown to increase mean alosetron plasma concentrations (AUC) approximately 6-fold and prolong the half-life by approximately 3-fold [see Drug Interactions ( 7.1 )] . (एलोसेट्रॉन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Concomitant administration of alosetron and moderate CYP1A2 inhibitors, including quinolone antibiotics and cimetidine, has not been evaluated, but should be avoided unless clinically necessary because of similar potential drug interactions. (एलोसेट्रॉन लेबल, दवाओं के इंटरैक्शन)

Concomitant administration of alosetron and moderate CYP1A2 inhibitors, including quinolone antibiotics and cimetidine, has not been evaluated, but should be avoided unless clinically necessary because of similar potential drug interactions. (एलोसेट्रॉन लेबल, दवाओं के इंटरैक्शन)

Fluvoxamine, a known strong inhibitor of CYP1A2, has been shown to increase mean alosetron plasma concentrations (AUC) approximately 6-fold and prolong the half-life by approximately 3-fold [see Drug Interactions ( 7.1 )] . (एलोसेट्रॉन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Fluvoxamine, a known strong inhibitor of CYP1A2, has been shown to increase mean alosetron plasma concentrations (AUC) approximately 6-fold and prolong the half-life by approximately 3-fold [see Drug Interactions ( 7.1 )] . (एलोसेट्रॉन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Fluvoxamine, a known strong inhibitor of CYP1A2, has been shown to increase mean alosetron plasma concentrations (AUC) approximately 6-fold and prolong the half-life by approximately 3-fold [see Drug Interactions ( 7.1 )] . (एलोसेट्रॉन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (एलोसेट्रॉन लेबल, दवाओं के इंटरैक्शन)

CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (एलोसेट्रॉन लेबल, दवाओं के इंटरैक्शन)

CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (एलोसेट्रॉन लेबल, दवाओं के इंटरैक्शन)

CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (एलोसेट्रॉन लेबल, दवाओं के इंटरैक्शन)

CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (एलोसेट्रॉन लेबल, दवाओं के इंटरैक्शन)

CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (एलोसेट्रॉन लेबल, दवाओं के इंटरैक्शन)

CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (एलोसेट्रॉन लेबल, दवाओं के इंटरैक्शन)

CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (एलोसेट्रॉन लेबल, दवाओं के इंटरैक्शन)

CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (एलोसेट्रॉन लेबल, दवाओं के इंटरैक्शन)

CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (एलोसेट्रॉन लेबल, दवाओं के इंटरैक्शन)

Examples: alosetron, anticholinergics, opioids Table 3: Established and Other Potentially Clinically Relevant Interactions Affecting Drugs Co-Administered with VIBERZI OATP1B1 and BCRP Substrate Clinical Impact: VIBERZI may increase the exposure of co-administered OATP1B1 and BCRP substrates. (एलक्साडोलिन लेबल, दवाओं के इंटरैक्शन)

CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (एलोसेट्रॉन लेबल, दवाओं के इंटरैक्शन)

CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (एलोसेट्रॉन लेबल, दवाओं के इंटरैक्शन)

Ketoconazole increased mean alosetron plasma concentrations (AUC) by 29%. (एलोसेट्रॉन लेबल, दवाओं के इंटरैक्शन)

CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (एलोसेट्रॉन लेबल, दवाओं के इंटरैक्शन)

CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (एलोसेट्रॉन लेबल, दवाओं के इंटरैक्शन)

In patients taking AUBAGIO, exposure of drugs metabolized by CYP1A2 (e.g., alosetron, duloxetine, theophylline, tizanidine) may be reduced. (टेरिफ्लुनोमाइड लेबल, दवाओं के इंटरैक्शन)

CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (एलोसेट्रॉन लेबल, दवाओं के इंटरैक्शन)

CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (एलोसेट्रॉन लेबल, दवाओं के इंटरैक्शन)

CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (एलोसेट्रॉन लेबल, दवाओं के इंटरैक्शन)

CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (एलोसेट्रॉन लेबल, दवाओं के इंटरैक्शन)

CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (एलोसेट्रॉन लेबल, दवाओं के इंटरैक्शन)

CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (एलोसेट्रॉन लेबल, दवाओं के इंटरैक्शन)

CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (एलोसेट्रॉन लेबल, दवाओं के इंटरैक्शन)

CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (एलोसेट्रॉन लेबल, दवाओं के इंटरैक्शन)

CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (एलोसेट्रॉन लेबल, दवाओं के इंटरैक्शन)

Effects of Primaquine on the Pharmacokinetics of Other Drugs CYP1A2 Substrates Published clinical and non-clinical reports indicate primaquine inhibits CYP1A2 enzyme activity and thus may lead to increased exposure of CYP1A2 substrate drugs (e.g., duloxetine, alosetron, theophylline and tizanidine) when co-administered with Primaquine phosphate Tablets. (प्राइमाक्वीन लेबल, दवाओं के इंटरैक्शन)

CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (एलोसेट्रॉन लेबल, दवाओं के इंटरैक्शन)

CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (एलोसेट्रॉन लेबल, दवाओं के इंटरैक्शन)

CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (एलोसेट्रॉन लेबल, दवाओं के इंटरैक्शन)

CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (एलोसेट्रॉन लेबल, दवाओं के इंटरैक्शन)

CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (एलोसेट्रॉन लेबल, दवाओं के इंटरैक्शन)

CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (एलोसेट्रॉन लेबल, दवाओं के इंटरैक्शन)

CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (एलोसेट्रॉन लेबल, दवाओं के इंटरैक्शन)

CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (एलोसेट्रॉन लेबल, दवाओं के इंटरैक्शन)

In patients taking ARAVA, exposure of drugs metabolized by CYP1A2 (e.g., alosetron, duloxetine, theophylline, tizanidine) may be reduced. (लेफ्लुनोमाइड लेबल, दवाओं के इंटरैक्शन)

CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (एलोसेट्रॉन लेबल, दवाओं के इंटरैक्शन)

CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (एलोसेट्रॉन लेबल, दवाओं के इंटरैक्शन)

CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (एलोसेट्रॉन लेबल, दवाओं के इंटरैक्शन)

CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (एलोसेट्रॉन लेबल, दवाओं के इंटरैक्शन)

CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (एलोसेट्रॉन लेबल, दवाओं के इंटरैक्शन)

CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (एलोसेट्रॉन लेबल, दवाओं के इंटरैक्शन)

Although not studied with alosetron, inhibition of N-acetyltransferase may have clinically relevant consequences for drugs such as isoniazid, procainamide, and hydralazine. (एलोसेट्रॉन लेबल, दवाओं के इंटरैक्शन)

Although not studied with alosetron, inhibition of N-acetyltransferase may have clinically relevant consequences for drugs such as isoniazid, procainamide, and hydralazine. (एलोसेट्रॉन लेबल, दवाओं के इंटरैक्शन)

Although not studied with alosetron, inhibition of N-acetyltransferase may have clinically relevant consequences for drugs such as isoniazid, procainamide, and hydralazine. (एलोसेट्रॉन लेबल, दवाओं के इंटरैक्शन)

Another study showed that alosetron had no clinically significant effect on plasma concentrations of the oral contraceptive agents ethinyl estradiol and levonorgestrel (CYP3A4 substrates). (एलोसेट्रॉन लेबल, दवाओं के इंटरैक्शन)

Another study showed that alosetron had no clinically significant effect on plasma concentrations of the oral contraceptive agents ethinyl estradiol and levonorgestrel (CYP3A4 substrates). (एलोसेट्रॉन लेबल, दवाओं के इंटरैक्शन)

The effect on CYP1A2 was explored further in a clinical interaction study with theophylline and no effect on metabolism was observed. (एलोसेट्रॉन लेबल, दवाओं के इंटरैक्शन)

The effect on CYP1A2 was explored further in a clinical interaction study with theophylline and no effect on metabolism was observed. (एलोसेट्रॉन लेबल, दवाओं के इंटरैक्शन)

The effect on CYP1A2 was explored further in a clinical interaction study with theophylline and no effect on metabolism was observed. (एलोसेट्रॉन लेबल, दवाओं के इंटरैक्शन)

Another study showed that alosetron had no clinically significant effect on plasma concentrations of the oral contraceptive agents ethinyl estradiol and levonorgestrel (CYP3A4 substrates). (एलोसेट्रॉन लेबल, दवाओं के इंटरैक्शन)

Another study showed that alosetron had no clinically significant effect on plasma concentrations of the oral contraceptive agents ethinyl estradiol and levonorgestrel (CYP3A4 substrates). (एलोसेट्रॉन लेबल, दवाओं के इंटरैक्शन)

Another study showed that alosetron had no clinically significant effect on plasma concentrations of the oral contraceptive agents ethinyl estradiol and levonorgestrel (CYP3A4 substrates). (एलोसेट्रॉन लेबल, दवाओं के इंटरैक्शन)

Another study showed that alosetron had no clinically significant effect on plasma concentrations of the oral contraceptive agents ethinyl estradiol and levonorgestrel (CYP3A4 substrates). (एलोसेट्रॉन लेबल, दवाओं के इंटरैक्शन)

The effect on CYP1A2 was explored further in a clinical interaction study with theophylline and no effect on metabolism was observed. (एलोसेट्रॉन लेबल, दवाओं के इंटरैक्शन)

Another study showed that alosetron had no clinically significant effect on plasma concentrations of the oral contraceptive agents ethinyl estradiol and levonorgestrel (CYP3A4 substrates). (एलोसेट्रॉन लेबल, दवाओं के इंटरैक्शन)

Another study showed that alosetron had no clinically significant effect on plasma concentrations of the oral contraceptive agents ethinyl estradiol and levonorgestrel (CYP3A4 substrates). (एलोसेट्रॉन लेबल, दवाओं के इंटरैक्शन)

Another study showed that alosetron had no clinically significant effect on plasma concentrations of the oral contraceptive agents ethinyl estradiol and levonorgestrel (CYP3A4 substrates). (एलोसेट्रॉन लेबल, दवाओं के इंटरैक्शन)

Another study showed that alosetron had no clinically significant effect on plasma concentrations of the oral contraceptive agents ethinyl estradiol and levonorgestrel (CYP3A4 substrates). (एलोसेट्रॉन लेबल, दवाओं के इंटरैक्शन)

The effect on CYP1A2 was explored further in a clinical interaction study with theophylline and no effect on metabolism was observed. (एलोसेट्रॉन लेबल, दवाओं के इंटरैक्शन)

Another study showed that alosetron had no clinically significant effect on plasma concentrations of the oral contraceptive agents ethinyl estradiol and levonorgestrel (CYP3A4 substrates). (एलोसेट्रॉन लेबल, दवाओं के इंटरैक्शन)

Another study showed that alosetron had no clinically significant effect on plasma concentrations of the oral contraceptive agents ethinyl estradiol and levonorgestrel (CYP3A4 substrates). (एलोसेट्रॉन लेबल, दवाओं के इंटरैक्शन)

Another study showed that alosetron had no clinically significant effect on plasma concentrations of the oral contraceptive agents ethinyl estradiol and levonorgestrel (CYP3A4 substrates). (एलोसेट्रॉन लेबल, दवाओं के इंटरैक्शन)

Another study showed that alosetron had no clinically significant effect on plasma concentrations of the oral contraceptive agents ethinyl estradiol and levonorgestrel (CYP3A4 substrates). (एलोसेट्रॉन लेबल, दवाओं के इंटरैक्शन)

Another study showed that alosetron had no clinically significant effect on plasma concentrations of the oral contraceptive agents ethinyl estradiol and levonorgestrel (CYP3A4 substrates). (एलोसेट्रॉन लेबल, दवाओं के इंटरैक्शन)

The effect on CYP1A2 was explored further in a clinical interaction study with theophylline and no effect on metabolism was observed. (एलोसेट्रॉन लेबल, दवाओं के इंटरैक्शन)

Another study showed that alosetron had no clinically significant effect on plasma concentrations of the oral contraceptive agents ethinyl estradiol and levonorgestrel (CYP3A4 substrates). (एलोसेट्रॉन लेबल, दवाओं के इंटरैक्शन)

Another study showed that alosetron had no clinically significant effect on plasma concentrations of the oral contraceptive agents ethinyl estradiol and levonorgestrel (CYP3A4 substrates). (एलोसेट्रॉन लेबल, दवाओं के इंटरैक्शन)

The effect on CYP1A2 was explored further in a clinical interaction study with theophylline and no effect on metabolism was observed. (एलोसेट्रॉन लेबल, दवाओं के इंटरैक्शन)

The effect on CYP1A2 was explored further in a clinical interaction study with theophylline and no effect on metabolism was observed. (एलोसेट्रॉन लेबल, दवाओं के इंटरैक्शन)

The effect on CYP1A2 was explored further in a clinical interaction study with theophylline and no effect on metabolism was observed. (एलोसेट्रॉन लेबल, दवाओं के इंटरैक्शन)

The effect on CYP1A2 was explored further in a clinical interaction study with theophylline and no effect on metabolism was observed. (एलोसेट्रॉन लेबल, दवाओं के इंटरैक्शन)

The effect on CYP1A2 was explored further in a clinical interaction study with theophylline and no effect on metabolism was observed. (एलोसेट्रॉन लेबल, दवाओं के इंटरैक्शन)

Another study showed that alosetron had no clinically significant effect on plasma concentrations of the oral contraceptive agents ethinyl estradiol and levonorgestrel (CYP3A4 substrates). (एलोसेट्रॉन लेबल, दवाओं के इंटरैक्शन)

Another study showed that alosetron had no clinically significant effect on plasma concentrations of the oral contraceptive agents ethinyl estradiol and levonorgestrel (CYP3A4 substrates). (एलोसेट्रॉन लेबल, दवाओं के इंटरैक्शन)

Another study showed that alosetron had no clinically significant effect on plasma concentrations of the oral contraceptive agents ethinyl estradiol and levonorgestrel (CYP3A4 substrates). (एलोसेट्रॉन लेबल, दवाओं के इंटरैक्शन)

Another study showed that alosetron had no clinically significant effect on plasma concentrations of the oral contraceptive agents ethinyl estradiol and levonorgestrel (CYP3A4 substrates). (एलोसेट्रॉन लेबल, दवाओं के इंटरैक्शन)